Hyperuricemia and gout: New insights into pathogenesis and treatment

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 3, 2007, Pages 215-221

  Pillinger, Michael H ^a,b,c   Rosenthal, Pamela ^a,b   Abeles, Aryeh M ^b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALLOPURINOL; CD86 ANTIGEN; COLCHICINE; CORTICOTROPIN; FEBUXOSTAT; GUANOSINE TRIPHOSPHATE; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEIC ACID; PEGYLATED URICASE; PREDNISONE; STEROID; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URATE OXIDASE; URIC ACID; ANTIGOUT AGENT; CORTICOSTEROID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THIAZOLE DERIVATIVE;

ANTIGEN PRESENTING CELL; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PATHOGENESIS; PROPHYLAXIS; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT PLANNING; ANIMAL; IMMUNOLOGY;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLCHICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; THIAZOLES; URATE OXIDASE; URIC ACID;

EID: 38449085556     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;(8 Suppl 1):S1.
2. Terkeltaub RA, Ginsberg MH. The inflammatory reaction to crystals. Rheum Dis Clin North Am. 1988;14(2):353-64.
3. Terkeltaub R. Gout in 2006: The perfect storm. Bull NYU Hosp Jt Dis. 2006;64(1-2):82-6.
4. Schumacher HR Jr. Pathology of crystal deposition diseases. Rheum Dis Clin North Am. 1988;14(2):269-88.
5. Schumacher HR Jr. Crystal deposition disease. Curr Opin Rheumatol. 1997;9(3):251-2.
6. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425(6957):516-21.
7. Janeway CA, Jr. Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
8. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol. 2001;13(1):114-9.
9. Skoberne M, Beignon AS, Bhardwaj N. Danger signals: A time and space continuum. Trends Mol Med. 2004;10(6):251-7.
10. Andrews NW. Membrane repair and immunological danger. EMBO. Rep 2005;6(9):826-30.
11. Hu DE, Moore AM, Thomsen LL, Brindle KM. Uric acid promotes tumor immune rejection. Cancer Res. 2004;64(15):5059-62.
12. Shi Y, Galusha SA, Rock KL. Cutting edge: Elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J Immunol. 2006;176(7):3905-8.
13. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34(1):78-84.
14. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40(3):355-60.
15. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101-6.
16. Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int. 2004;66(1):281-7.
17. Feig DI, Rodriguez-Iturbe B, Nakagawa T, Johnson RJ. Nephron number, uric acid, and renal microvascular disease in the pathogenesis of essential hypertension. Hypertension. 2006;48(1):25-6.
18. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287-93.
19. Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283(5):F1105-10.
20. Feig DI, Mazzali M, Kang DH, et al. Serum uric acid: A risk factor and a target for treatment? J Am Soc Nephrol. 2006;17(4 Suppl 2):S69-73.
21. Feig DI, Johnson RJ. The role of uric acid in pediatric hypertension. J Ren Nutr. 2007;17(1):79-83.
22. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: Is the incidence rising? J Rheumatol. 2002;29(11):2403-6.
23. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31(8):1582-7.
24. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093- 103.
25. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;52(1):283-9.
26. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: A prospective study. Lancet. 2004;363(9417):1277-81.
27. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006;(8 Suppl 1):S4.
28. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447-52.
29. Hatch M, Freel RW, Shahinfar S, Vaziri ND. Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. J Pharmacol Exp Ther. 1996;276(1):187-93.
30. Lipkowitz MS, Leal-Pinto E, Rappoport JZ, et al. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest. 2001;107(9):1103-15.
31. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: First line of the immune response to cell stress. Cell. 2006;126(4):659-62.
32. Martinon F, Burns K, Tschopp J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417-26.
33. Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 2007;356(12):1216-25.
34. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-41.
35. Liu-Bryan R, Scott P, Sydlaske A, et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2005;52(9):2936-46.
36. Chen CJ, Shi Y, Hearn A, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006;116(8):2262-71.
37. Liu R, O'Connell M, Johnson K, et al. Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum. 2000;43(5):1145-55.
38. Schumacher HR Jr. Febuxostat: A non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drug. 2005;14(7):893-903.
39. Becker MA, Schumacher HR, Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-61.
40. Royer R, Vindel J, Lamarche M, Kissel P. [Modalities of purine excretion during enzyme treatment of gout and other hyperuricemic conditions with urate oxidase]. Presse Med. 1968;76(49):2325-7.
41. Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol. 2006;3(8):438-47.
42. Richette P, Bardin T. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol. 2006;2(6):338-42; quiz 343.
43. Sundy JS, Ganson NJ, Kelly SJ, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007;56(3):1021-8.
44. Randle JC, Harding MW, Ku G, et al. ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin Investig Drugs. 2001;10(7):1207-9.
45. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.